眼部頸動脈疼痛市場規模、佔有率和成長分析：按診斷方法、管理和治療方法、臨床相關性、最終用戶和地區分類－2026-2033年產業預測

2024 年全球眼部頸動脈疼痛市場價值為 150 億美元，預計到 2033 年將從 2025 年的 163.5 億美元成長至 325.8 億美元，預測期（2026-2033 年）複合年成長率為 9.0%。

眼部頸動脈疼痛市場受到人口老化和動脈粥狀硬化性心血管疾病日益普遍的顯著影響，後者常伴隨眼部缺血症狀，需要及時介入。由於延遲治療可能導致不可逆的視力喪失，該市場涵蓋診斷、血管內治療、外科手術治療以及輔助眼科護理。從外科切除術到高度先進的微創技術，該領域的發展凸顯了多學科診療的必要性。雙功能超音波和CTA（電腦斷層掃描）等先進診斷工具，以及遠端醫療和經濟實惠的影像解決方案，透過促進頸動脈相關眼部缺血的早期發現和治療，正在擴大市場潛力。此外，人工智慧（AI）正在促進協同診療，從而提高診斷準確性和治療策略，提升臨床效率，最終改善患者預後。

全球眼科頸動脈疼痛市場的成長要素

眼科醫師、神經科和血管專科醫師對眼部頸動脈疼痛的認知不斷提高，顯著提升了鑑別診斷中對該疾病的識別率，從而加快了診斷評估速度並促進了綜合診療策略的發展。這種臨床認知的提升促使醫療專業人員尋求專業的影像學檢查和治療方法，進而增加了對相關診斷工具和藥物的需求。此外，這種認知的提升也推動醫療機構建立專門的服務體係以滿足病患的需求。隨著越來越多的臨床醫生能夠準確識別並轉診患者，接受治療的病例數穩步成長，持續的臨床應用以及相關產品開發商的關注進一步推動了市場成長。

全球眼科頸動脈疼痛市場的限制因素

由於缺乏普遍認可的眼部頸動脈疼痛臨床指引或標準化治療通訊協定，醫療專業人員在最佳治療策略方面存在分歧。這種不確定性常常阻礙特定治療方法和診斷方法的常規應用。缺乏共識降低了臨床結果的可預測性，並導致醫療服務提供者和保險公司在將資源分配給專科服務和醫療設備時持謹慎態度。這種情況最終導致診療路徑的發展延遲、不願將特定治療方法納入處方集以及創新治療方法的商業化潛力降低，阻礙了製造商關注這個市場。

全球眼部頸動脈疼痛市場趨勢

全球眼科頸動脈疼痛市場正經歷著向標靶治療創新方向的顯著轉變，這主要得益於對基於機制的治療方法和眼科特異性給藥系統的關注。生技和專科製藥公司日益重視個人化治療方案，以降低全身暴露並提高耐受性。眼科、神經科和血管科相關人員的合作正在加速藥物從研發到臨床應用的轉化。各公司致力於開發差異化產品，並對其生命週期進行策略性管理，以滿足未被滿足的醫療需求，拓展適應症，並透過改善患者體驗和提供引人注目的臨床價值提案來建立競爭優勢。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球眼部頸動脈疼痛市場規模：依診斷方法分類

• 診斷影像
• 臨床症狀評估
• 發炎標記篩檢

全球眼部頸動脈疼痛市場規模：按管理和治療方法分類

• 非類固醇消炎劑（NSAIDs）
• 皮質類固醇
• 鈣離子通道阻斷劑

全球眼部頸動脈疼痛市場規模：臨床相關性別

• 特發性頸動脈疼痛
• TIPIC症候群

全球眼部頸動脈疼痛市場規模：依最終用戶分類

• 眼科專科診所
• 神經科診所
• 三級醫療醫院

全球眼部頸動脈疼痛市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要企業2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要企業的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要企業簡介

• Pfizer Inc.
• F. Hoffmann-La Roche
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Regeneron Pharmaceuticals
• Santen Pharmaceutical
• Genentech
• Allergan
• Bausch+Lomb
• AstraZeneca
• Johnson & Johnson
• Sun Pharma
• Lupin Limited
• Teva Pharmaceuticals
• Merck & Co.
• Amgen
• Eli Lilly
• GlaxoSmithKline
• Sanofi

結論與建議

Global Ocular Carotidynia Market size was valued at USD 15.0 Billion in 2024 and is poised to grow from USD 16.35 Billion in 2025 to USD 32.58 Billion by 2033, growing at a CAGR of 9.0% during the forecast period (2026-2033).

The ocular carotidynia market is significantly influenced by an aging demographic and the increasing prevalence of atherosclerotic cardiovascular diseases, which often present with ocular ischemic symptoms necessitating timely intervention. The market includes diagnostics, endovascular, surgical, and adjunctive ophthalmic care, as delays in treatment can lead to irreversible vision loss. The evolution of the field from surgical endarterectomy to advanced minimally invasive procedures highlights the need for multidisciplinary care. Enhanced diagnostic tools, such as duplex ultrasound and CTA, alongside telemedicine and affordable imaging solutions, are expanding market potential by facilitating early detection and treatment of carotid-related ocular ischemia. Furthermore, artificial intelligence is advancing diagnostic accuracy and treatment strategies, improving clinical efficiency, and fostering collaborative care pathways that ultimately enhance patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ocular Carotidynia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ocular Carotidynia Market Segments Analysis

Global ocular carotidynia market is segmented by diagnostic approach, management/treatment modality, clinical association, end-user and region. Based on diagnostic approach, the market is segmented into Imaging, Clinical Symptoms Assessment and Inflammatory Marker Screening. Based on management/treatment modality, the market is segmented into Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids and Calcium Channel Blockers. Based on clinical association, the market is segmented into Idiopathic Carotidynia and TIPIC Syndrome. Based on end-user, the market is segmented into Ophthalmology Specialized Centers, Neurology Clinics and Tertiary Care Hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ocular Carotidynia Market

The growing awareness of ocular carotidynia among ophthalmologists, neurologists, and vascular specialists has significantly enhanced the condition's visibility in differential diagnoses, resulting in more prompt diagnostic evaluations and integrated care strategies. This increased clinical recognition drives healthcare professionals to pursue specialized imaging and therapeutic alternatives, leading to a rising demand for associated diagnostic tools and medications. Moreover, this awareness propels healthcare facilities to establish focused services to address patient needs. As more clinicians accurately identify and refer patients, the volume of treated cases steadily increases, further fueling market growth through continued clinical application and interest from developers of related products.

Restraints in the Global Ocular Carotidynia Market

The absence of universally accepted clinical guidelines and standardized treatment protocols for ocular carotidynia leads to ambiguity among healthcare professionals concerning the best management strategies. This uncertainty often hinders the routine implementation of particular therapies and diagnostic methods. A lack of consensus can diminish the predictability of clinical outcomes, causing providers and payers to be wary of investing resources in specialized services or devices. This situation ultimately results in a slower development of care pathways, reluctance to include certain therapies in formularies, and a decreased likelihood of commercialization for innovative treatments, discouraging manufacturers from focusing on this market.

Market Trends of the Global Ocular Carotidynia Market

The Global Ocular Carotidynia market is witnessing a notable shift towards innovation in targeted therapies, driven by a focus on mechanism-driven treatments and ocular-specific delivery systems. Biotech firms and specialty pharmaceutical companies are increasingly prioritizing personalized therapeutic approaches that mitigate systemic exposure while enhancing tolerability. Collaborative efforts among stakeholders in ophthalmology, neurology, and vascular medicine are facilitating the transition from discovery to clinical application. Companies are concentrating on developing differentiated assets and strategic lifecycle management to address unmet medical needs, broaden treatment indications, and foster competitive advantages through improved patient experiences and compelling clinical value propositions.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Ocular Carotidynia Market Size by Diagnostic Approach & CAGR (2026-2033)

• Market Overview
• Imaging
• Clinical Symptoms Assessment
• Inflammatory Marker Screening

Global Ocular Carotidynia Market Size by Management/Treatment Modality & CAGR (2026-2033)

• Market Overview
• Non-steroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids
• Calcium Channel Blockers

Global Ocular Carotidynia Market Size by Clinical Association & CAGR (2026-2033)

• Market Overview
• Idiopathic Carotidynia
• TIPIC Syndrome

Global Ocular Carotidynia Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Ophthalmology Specialized Centers
• Neurology Clinics
• Tertiary Care Hospitals

Global Ocular Carotidynia Market Size & CAGR (2026-2033)

• North America (Diagnostic Approach, Management/Treatment Modality, Clinical Association, End-User)
  • US
  • Canada
• Europe (Diagnostic Approach, Management/Treatment Modality, Clinical Association, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnostic Approach, Management/Treatment Modality, Clinical Association, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnostic Approach, Management/Treatment Modality, Clinical Association, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnostic Approach, Management/Treatment Modality, Clinical Association, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch + Lomb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations